238 related articles for article (PubMed ID: 11966509)
21. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
22. Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.
Saslow SB; Scolapio JS; Camilleri M; Forstrom LA; Thomforde GM; Burton DD; Rubin J; Pitot HC; Zinsmeister AR
Gut; 1998 May; 42(5):628-34. PubMed ID: 9659155
[TBL] [Abstract][Full Text] [Related]
23. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers.
De Schryver AM; Andriesse GI; Samsom M; Smout AJ; Gooszen HG; Akkermans LM
Aliment Pharmacol Ther; 2002 Mar; 16(3):603-12. PubMed ID: 11876716
[TBL] [Abstract][Full Text] [Related]
24. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
25. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
[TBL] [Abstract][Full Text] [Related]
26. Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial.
Stacher G; Weber U; Stacher-Janotta G; Bauer P; Huber K; Holzäpfel A; Krause G; Steinborn C
Br J Clin Pharmacol; 2000 May; 49(5):429-36. PubMed ID: 10792200
[TBL] [Abstract][Full Text] [Related]
27. Abnormal colonic propagated activity in patients with slow transit constipation and constipation-predominant irritable bowel syndrome.
Bassotti G; Chistolini F; Marinozzi G; Morelli A
Digestion; 2003; 68(4):178-83. PubMed ID: 14671425
[TBL] [Abstract][Full Text] [Related]
28. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
Maxton DG; Morris J; Whorwell PJ
Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
[TBL] [Abstract][Full Text] [Related]
29. Effects of oral cisapride on small bowel motility in irritable bowel syndrome.
Evans PR; Bak YT; Kellow JE
Aliment Pharmacol Ther; 1997 Oct; 11(5):837-44. PubMed ID: 9354190
[TBL] [Abstract][Full Text] [Related]
30. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Viramontes BE; Camilleri M; McKinzie S; Pardi DS; Burton D; Thomforde GM
Am J Gastroenterol; 2001 Sep; 96(9):2671-6. PubMed ID: 11569693
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
32. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
33. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
34. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
[TBL] [Abstract][Full Text] [Related]
35. Alosetron for irritable bowel syndrome.
Barbehenn E; Lurie P; Wolfe SM
Lancet; 2000 Dec; 356(9246):2009-10. PubMed ID: 11130544
[No Abstract] [Full Text] [Related]
36. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
37. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
[TBL] [Abstract][Full Text] [Related]
38. Alosetron: a new therapy for irritable bowel syndrome.
Kupecz D
Nurse Pract; 2000 Jul; 25(7):95-6, 98-100. PubMed ID: 10916831
[No Abstract] [Full Text] [Related]
39. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
40. Alosetron approved for treatment of irritable bowel syndrome.
Miller JL
Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
